Division of Plastic Surgery, Department of Surgery, University of Pennsylvania Health System, Penn Presbyterian Hospital, 51 North 39th Street, Wright Saunders Building, Philadelphia, PA, 19104, USA.
Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA.
Hernia. 2021 Jun;25(3):717-726. doi: 10.1007/s10029-021-02394-9. Epub 2021 Apr 27.
Despite continued efforts, recurrence after ventral hernia repair (VHR) remains a common problem. Biosynthetic Phasix (Poly-4-Hydroxybutyrate, P4HB) mesh combines the durability of synthetic mesh with the bio-resistance of biologics. P4HB has shown promising early outcomes, but long-term data are lacking. We examine patients following VHR with P4HB with at least 3 years of follow-up to assess clinical and patient reported outcomes (PROs).
Adult patients (≥ 18 years old) undergoing VHR with P4HB mesh between 10/2015 and 01/2018 by a single surgeon were retrospectively identified. Patients with < 36 months of follow-up were excluded unless they had a documented recurrence. Clinical outcomes and quality of life using the Hernia-Related Quality of Life Survey (HerQLes) were assessed.
Seventy-one patients were included with a median age and body mass index of 61.2 and 31 kg/m, respectively. Mesh was placed in the retromuscular (79%) and onlay (21%) planes with 1/3 of patients having hernias repaired in contaminated fields. There were no mesh infections, enterocutaneous fistulas, or mesh explantations. Nine patients (12.7%) developed recurrence at a median follow-up of 43.1 months [38.2-49.1]. Mesh plane, fixation technique, and Ventral Hernia Working Group were not associated with recurrence. Significant improvement in disease-specific PROs was observed and maintained at 3-year follow-up.
Longitudinal clinical and quality of life outcomes after clean and contaminated VHR with P4HB are limited. Here, we conclude that P4HB is an effective and versatile mesh option for use in abdominal wall reinforcement.
尽管不断努力,腹疝修补术后(VHR)的复发仍然是一个常见的问题。生物合成 Phasix(聚-4-羟基丁酸酯,P4HB)网片结合了合成网片的耐用性和生物制品的生物抗性。P4HB 早期结果显示出良好的前景,但缺乏长期数据。我们检查了至少随访 3 年接受 P4HB 行 VHR 的患者,以评估临床和患者报告的结果(PROs)。
回顾性地确定了 2015 年 10 月至 2018 年 1 月期间由一位外科医生对 P4HB 网片行 VHR 的成年患者(≥18 岁)。排除随访时间<36 个月的患者,除非有记录的复发。使用疝相关生活质量调查(HerQLes)评估临床结果和生活质量。
共纳入 71 例患者,中位年龄和体重指数分别为 61.2 和 31kg/m。网片分别置于肌后(79%)和上置(21%)平面,1/3 的患者疝修补在污染区域。无网片感染、肠皮肤瘘或网片取出。9 例患者(12.7%)在中位随访 43.1 个月(38.2-49.1)时复发。网片平面、固定技术和腹壁疝工作组与复发无关。在 3 年随访时观察到并维持了疾病特异性 PROs 的显著改善。
在清洁和污染的 VHR 中使用 P4HB 的纵向临床和生活质量结果有限。在这里,我们得出结论,P4HB 是一种有效的、多功能的腹壁加固网片选择。